ZIOP ZIOPHARM Oncology Inc.

Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the financial results and provide a corporate update.

Register for the live webcast using the link or by visiting the “Investors” section of the Alaunos website at . To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The event will be archived on the Company’s website for approximately 30 days after the call.

About Alaunos Therapeutics, Inc.

Alaunos Therapeutics is a leader in the science of T-cell receptor (TCR) cell therapy working to revolutionize solid cancer treatment and outcomes. The clinical-stage company’s TCR T-cell therapy (TCR-T) is one of the most advanced TCR programs targeting driver mutations in solid tumors with an ongoing Phase 1/2 trial of its TCR-T product candidates across six solid cancers. Alaunos is powered by two proprietary platforms: its elegantly efficient non-viral Sleeping Beauty cell engineering platform; and its hunTR® discovery platform, which is expanding its industry-leading library of TCRs against high-frequency driver mutations. Alaunos is a part of an ongoing collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), working to advance the science of TCR therapy. For more information, visit .

Investor Relations Contact:

Alex Lobo

Stern Investor Relations

Media Contact:

Heather Anderson

6 Degrees PR



EN
03/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZIOPHARM Oncology Inc.

 PRESS RELEASE

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, P...

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patientshunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations, including KRAS and TP53Company continues to explore potential strategic alternatives; cost-savings measures expected to extend cash runaway into the second quar...

 PRESS RELEASE

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, ...

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patientsCompany to wind down TCR-T Library Phase 1/2 trial and concurrently explore potential partnering opportunities for the hunTR® platform as well as broad strategic alternativesReducing headcount by approximately 60% while retaining key hunTR® R&D capabilities HOUS...

 PRESS RELEASE

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global S...

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Company will present at the 2nd Hawaii Global Summit on Thoracic Malignancies taking place June 27 – July 1, 2023. Alaunos Director of Translational Sciences Matthew Collinson-Pautz, Ph.D., will discuss the Company’s TCR-T therapy...

 PRESS RELEASE

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/...

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indicationsTreatment was well tolerated with a manageable safety profile and persistence of TCR-T cells in peripheral blood observed in all three treated patients at last follow-upProof-of-concept demonstrated for non-viral Sleeping Beauty cell engineering platform in effective manufa...

 PRESS RELEASE

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

Alaunos Therapeutics Reports First Quarter 2023 Financial Results Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023Fully prepaid loan with Silicon Valley Bank; now a debt-free companyAmended exclusive licensing agreement with Precigen, Inc., reflecting the Company’s focus on its TCR-T programs and eliminating long-term financial obligationsCompany to host conference call today at 9:00 a.m. ET HOUSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch